Literature DB >> 16401156

Defining response in clinical trials for obsessive-compulsive disorder: a signal detection analysis of the Yale-Brown obsessive compulsive scale.

David F Tolin1, Jonathan S Abramowitz, Gretchen J Diefenbach.   

Abstract

OBJECTIVE: Many studies of the treatment of obsessive-compulsive disorder (OCD) have used percent reduction cutoffs on the Yale-Brown Obsessive Compulsive Scale (YBOCS) to classify patients as treatment responders. However, reduction criteria have varied from 20% to 50%, with studies of cognitive-behavioral therapy (CBT) using a more stringent criterion than studies of pharmacotherapy. The aim of this retrospective investigation was to determine optimal YBOCS reduction criteria for classifying patients as responders.
METHOD: Data from 87 adult clinic and research outpatients meeting DSM-IV-TR criteria for OCD according to structured interview were examined, comparing the percent YBOCS reduction from pretreatment to posttreatment with 2 "gold standard" criteria from the Clinical Global Impressions (CGI) scale: much or very much improved and mild illness or better. Signal detection analyses were used to determine the sensitivity, specificity, predictive value of a positive test, predictive value of a negative test, and efficiency of various YBOCS reduction cutoffs.
RESULTS: A YBOCS reduction cutoff of 30% was optimal for predicting improvement on the CGI. The 20% cutoff used by many pharmacologic studies resulted in a high number of false positives, whereas the 50% cutoff used by most CBT studies resulted in a high number of false negatives. For predicting mild illness or better at posttreatment, a YBOCS reduction cutoff of 40% to 50% was optimal.
CONCLUSIONS: A YBOCS reduction criterion of 30% appears to be optimal for determining clinical improvement, whereas a 40% to 50% reduction criterion is appropriate for predicting mild illness at posttreatment. Future studies should employ a standard definition of treatment response in order to facilitate cross-study comparisons.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16401156     DOI: 10.4088/jcp.v66n1209

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  36 in total

1.  Minocycline augmentation of pharmacotherapy in obsessive-compulsive disorder: an open-label trial.

Authors:  Carolyn I Rodriguez; James Bender; Sue M Marcus; Michael Snape; Moira Rynn; Helen Blair Simpson
Journal:  J Clin Psychiatry       Date:  2010-09       Impact factor: 4.384

2.  Defining treatment response in pediatric tic disorders: a signal detection analysis of the Yale Global Tic Severity Scale.

Authors:  Eric A Storch; Alessandro S De Nadai; Adam B Lewin; Joseph F McGuire; Anna M Jones; P Jane Mutch; R Doug Shytle; Tanya K Murphy
Journal:  J Child Adolesc Psychopharmacol       Date:  2011-11-09       Impact factor: 2.576

3.  Cognitive behavior therapy augmentation of pharmacotherapy in pediatric obsessive-compulsive disorder: the Pediatric OCD Treatment Study II (POTS II) randomized controlled trial.

Authors:  Martin E Franklin; Jeffrey Sapyta; Jennifer B Freeman; Muniya Khanna; Scott Compton; Daniel Almirall; Phoebe Moore; Molly Choate-Summers; Abbe Garcia; Aubrey L Edson; Edna B Foa; John S March
Journal:  JAMA       Date:  2011-09-21       Impact factor: 56.272

4.  Side-effects of SSRIs disrupt multimodal treatment for pediatric OCD in a randomized-controlled trial.

Authors:  Adam M Reid; Joseph P H McNamara; Tanya K Murphy; Andrew G Guzick; Eric A Storch; Wayne K Goodman; Gary R Geffken; Regina Bussing
Journal:  J Psychiatr Res       Date:  2015-10-14       Impact factor: 4.791

5.  Towards an international expert consensus for defining treatment response, remission, recovery and relapse in obsessive-compulsive disorder.

Authors:  David Mataix-Cols; Lorena Fernández de la Cruz; Ashley E Nordsletten; Fabian Lenhard; Kayoko Isomura; Helen Blair Simpson
Journal:  World Psychiatry       Date:  2016-02       Impact factor: 49.548

6.  Detecting a clinically meaningful change in tic severity in Tourette syndrome: a comparison of three methods.

Authors:  Sangchoon Jeon; John T Walkup; Douglas W Woods; Alan Peterson; John Piacentini; Sabine Wilhelm; Lily Katsovich; Joseph F McGuire; James Dziura; Lawrence Scahill
Journal:  Contemp Clin Trials       Date:  2013-08-31       Impact factor: 2.226

7.  Defining Treatment Response and Remission in Youth Anxiety: A Signal Detection Analysis With the Multidimensional Anxiety Scale for Children.

Authors:  Sophie A Palitz; Nicole E Caporino; Joseph F McGuire; John Piacentini; Anne Marie Albano; Boris Birmaher; John T Walkup; Scott N Compton; Golda S Ginsburg; Philip C Kendall
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2018-04-17       Impact factor: 8.829

8.  Establishing Clinical Cutoffs for Response and Remission on the Screen for Child Anxiety Related Emotional Disorders (SCARED).

Authors:  Nicole E Caporino; Dara Sakolsky; Douglas M Brodman; Joseph F McGuire; John Piacentini; Tara S Peris; Golda S Ginsburg; John T Walkup; Satish Iyengar; Philip C Kendall; Boris Birmaher
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2017-06-06       Impact factor: 8.829

9.  Refining Clinical Judgment of Treatment Response and Symptom Remission Identification in Childhood Anxiety Using a Signal Detection Analysis on the Pediatric Anxiety Rating Scale.

Authors:  Carly J Johnco; Alison Salloum; Adam B Lewin; Eric A Storch
Journal:  J Child Adolesc Psychopharmacol       Date:  2015-11       Impact factor: 2.576

10.  Current trends in drug treatment of obsessive-compulsive disorder.

Authors:  Eric H Decloedt; Dan J Stein
Journal:  Neuropsychiatr Dis Treat       Date:  2010-05-25       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.